1
|
Moy JN, Amin AM, Chalmers-Watson C, Chowdhury R, Forssten C, Fu J, Ghosh S, Harris JD, Kordowich S, Li Y, Lin W, Mackay-Thomas S, Mickiewicz M, Patel N, Resino S, Sevenoaks T, Tugetman MA, Valencia J, Vijesurier R, White N, Woods CW, Kennedy PT, Ryan P. Evaluation of the Panbio™ COVID-19 IgG rapid test device performance. Heliyon 2023; 9:e22612. [PMID: 38125420 PMCID: PMC10730567 DOI: 10.1016/j.heliyon.2023.e22612] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2023] [Revised: 11/13/2023] [Accepted: 11/15/2023] [Indexed: 12/23/2023] Open
Abstract
Background The Panbio™ COVID-19 IgG Rapid Test Device ("Panbio™") detects IgG antibodies against the SARS-CoV-2 spike protein from viral infection or vaccination. Objectives To determine the diagnostic sensitivity and specificity of the Panbio™ professional use test, using fingerstick whole blood and venous plasma. Study design Fingerstick whole blood and venous plasma from each participant were tested with Panbio™ and compared against the SARS-CoV-2 IgG II assay on the Abbott Architect™ platform (Europe) or the equivalent AdviseDx SARS-CoV-2 IgG II Abbott Alinity i™ platform (US). 447 evaluable participants were enrolled across 6 US and 9 European clinical centers. Results For unvaccinated participants with PCR-confirmed infection ≥21 days post-symptom onset, the Panbio™ sensitivity with fingerstick whole blood was 92.6 % (95 % CI: 85.9, 96.7), and the specificity was 97.0 % (95 % CI: 93.1, 99.0). For venous plasma, the sensitivity was 90.0 % (95 % CI: 79.5, 96.2) for participants with PCR-confirmed infection and symptom onset 22-180 days ago; the specificity was 96.3 % (92.2, 98.6). For vaccinated participants, the sensitivity was 98.4 % (95 % CI: 91.2, 100.0) for fingerstick whole blood and 96.7 % (95 % CI: 88.7, 99.6) for venous plasma. Conclusion The Panbio™ test had high sensitivity and specificity for detecting IgG against the SARS-CoV-2 spike protein.
Collapse
Affiliation(s)
- James N. Moy
- Department of Internal Medicine, Rush University Medical Center, Chicago, IL, USA
| | | | | | | | | | - Jun Fu
- Department of Internal Medicine, Rush University Medical Center, Chicago, IL, USA
| | | | - Jeffrey D. Harris
- Urgent Care Clinical Trials at AFC Urgent Care, Easley and Powdersville, SC, USA
| | | | - Yin Li
- Abbott Rapid and Molecular Diagnostics, Carlsbad, CA, USA
| | - Wenchi Lin
- Abbott Rapid and Molecular Diagnostics, Galway, Ireland
| | | | - Marc Mickiewicz
- Urgent Care Clinical Trials at Complete Urgent Care, Nashville, TN, USA
| | | | - Salvador Resino
- Centro de Investigación Biomédica en Red en Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain
- Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Spain
| | | | | | - Jorge Valencia
- Servicio de Medicina Interna, Hospital Universitario Infanta Leonor, Madrid, Spain
| | - Roy Vijesurier
- Abbott Rapid and Molecular Diagnostics, Abbott Park, IL, USA
| | - Nikki White
- The Princess Alexandra Hospital NHS Trust, Essex, UK
| | - Christopher W. Woods
- Center for Infectious Disease Diagnostic and Innovation, Duke University School of Medicine, Durham, NC, USA
| | | | - Pablo Ryan
- Centro de Investigación Biomédica en Red en Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain
- Servicio de Medicina Interna, Hospital Universitario Infanta Leonor, Madrid, Spain
- Universidad complutense de Madrid, Madrid, Spain
| |
Collapse
|